Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
4
×
amgen
4
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
4
×
new york blog main
new york top stories
novartis
abeona therapeutics
biotech
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
fda
inclisiran
indiana blog main
indiana top stories
medicare
national
new york
pcsk9 inhibitors
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
rna interference
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
sanofi
seattle blog main
seattle top stories
texas blog main
texas top stories
the medicines company
What
drug
bio
brings
cholesterol
fda
market
medco
medicines
new
roundup
acquire
advantages
agreed
alzheimer’s
bar
billion
bringing
cash
clears
closer
company
compound
congress
deal
democrats
divided
elections
expect
fallout
filing
gamble
inched
losses
lowering
medco’s
midterm
morning
mover
novartis
panel
Language
unset
Current search:
amgen
×
" national top stories "
×
" alnylam pharmaceuticals "
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
